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1. Abstract 
Degree Project, Programme in Medicine, “Validity of heart failure diagnosis in patients with 
obesity” by Karin Andréasson, 2018, Institute of Medicine, Gothenburg, Sweden 
1.1 Background 
Heart failure (HF) is a syndrome affecting the function of the heart where the main symptoms 
are dyspnea, fatigue and peripheral edema. Patients with obesity often present similar 
symptoms to those seen in HF, and diagnosing HF in this patient group is known to provide 
some difficulty. The validity of HF diagnosis in the Swedish discharge register has previously 
been shown to be high, but the validity in patients with concurrent obesity has not been 
investigated. 
1.2 Methods and results 
The study population consisted of all patients registered with a diagnostic code of obesity at 
the Obesity Care Unit (2000-2006) or at the Regional Obesity Centre (2007-2017) and who 
had a concurrent HF code either at Sahlgrenska university hospital or at the nearby Kungälv 
hospital, both in western Sweden. Relevant information from patient records was filled in 
using a form designed for the purpose of this study. The HF diagnosis was then classified as 
definite, probable or miscoded by a team consisting of a medical student and an experienced 
cardiologist. Out of 8,202 obese patients, 77 had a HF diagnosis.  After exclusions, HF could 
be validated in 45 patients. Of these, 64.4 % were classified as definite, 33.3 % as probable 
and 2.2 % as miscoded, which is comparable to a prior study in unselected HF patients.  
1.3 Conclusion 
The validity of HF diagnosis in obese patients is comparable to the validity in patients without 
obesity. Because of the limited size of this study population, further and larger studies are 
needed to verify these results.   
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1.4 Key words 
Heart failure, validation, obesity, diagnosis  
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2. Background 
Heart failure (HF) is a serious and common condition. The prevalence of HF in Sweden is 
estimated to 2 % which is comparable to the prevalence in the rest of the western world (1, 2). 
Incidence of HF has been decreasing in the general population since the mid-1990’s, except in 
the young ≤ 45 years where incidence and prevalence are increasing (1, 3). In established HF, 
5-year mortality of is estimated at about 50 % and the lifetime risk of HF is one in five in both 
men and women (4). Risk factors for HF are coronary heart disease, diabetes, valvular heart 
disease, hypertension, smoking and obesity (5). 
 
The prevalence of obesity is increasing worldwide. According to the recent WHO report on 
non-communicable diseases, 39 % of all adults over the age of 18 are currently overweight, 
defined as having a body mass index (BMI) ≥ 25 kg/m2, and the prevalence of obesity 
(defined as having a BMI ≥ 30 kg/m2) was 15 % in women and 11 % in men. This is almost 
twice as high as the prevalence in 1980 (6). Obesity is a major risk factor for cardiovascular 
disease and type II diabetes, as well as a risk factor in some cancers (7, 8).  
 
The effect of obesity on the cardiovascular system can partly be explained through 
dyslipidemia, hypertension and hyperglycemia, including diabetes (9). Previous studies have 
shown that obesity also plays a role independently of these factors, with a stepwise increase in 
the risk of a future HF diagnosis for each BMI unit, starting already at levels that are 
considered normal (10). In contrast, mortality in HF may be lower in patients who are 
overweight or obese (11). Further studies regarding the effect of weight loss on HF mortality 
are needed to further clarify this seemingly paradoxical relationship.  
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There is no unequivocal definition of HF, which can make diagnosis difficult. To aid 
clinicians there are several available guidelines. Since 1995, the European Society of 
Cardiology (ESC) regularly publishes updated guidelines on the diagnosis and management of 
HF. According to the ESC, a diagnosis of HF requires the presence of symptoms, clinical 
signs (from 2008) and objective evidence. Classical symptoms of HF are dyspnea, fatigue and 
limited physical activity and typical signs are rales, peripheral edema and a third heart sound, 
S3 (12-18). Clinicians in Europe generally have a high awareness of the ESC guidelines. This 
also applies specifically to Swedish clinicians where 71 % of Swedish cardiologists have 
reported that they adhere closely to the ESC guidelines in clinical practice (19). 
 
There have been previous studies evaluating how well the ESC guidelines for diagnosing HF 
are followed in clinical praxis in Sweden. One study investigating 317 men with a diagnosis 
of HF in the Swedish hospital discharge registry found that 82 % of the diagnoses of could be 
classified as “definite” cases and 16 % as “questionable” in concordance with the ESC 
guidelines (20). An as yet not published study in Gothenburg looking at the validity of HF 
diagnosis in the discharge register of Sahlgrenska university hospital in western Sweden 
found that 62.3 % of HF diagnoses could be classified as “definite”, 32.1 % as “probable” and 
5.6 % as “miscoded” (Schaufelberger M et al, Validity of the heart failure diagnosis in 
Western Sweden 2000 – 2012, manuscript). These studies investigated unselected patients 
with a discharge diagnosis of HF but it is still unknown how the validity of the diagnosis may 
be affected by concurrent obesity, which may present with similar symptoms. 
 
Diagnosing HF in patients with obesity provides several challenges. Common symptoms of 
HF include dyspnea, swelling of the lower legs and reduced exercise tolerance (18), 
symptoms which are also commonly present in obese patients. As the diagnosis of HF relies 
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heavily on the presence of symptoms this can be problematic. Symptoms of HF have been 
shown to be present to a greater extent in obese patients with HF compared to patients with 
normal BMI (11). Signs of HF are generally present to a lower extent in patients with 
concurrent obesity, with the exception of edema which is seen more often (11). Obesity may 
also provide difficulties in the interpretation of echocardiographic images as these are more 
often of poor quality in obese patients (21). 
 
Another potential difficulty in diagnosing HF in patients with obesity is interpretation of 
natriuretic peptide concentration. Testing levels of the natriuretic peptides Brain Natriuretic 
peptide (BNP) and N-terminal prohormone of BNP (NT-proBNP) are now well-established 
tools in diagnosing HF, where raised levels of natriuretic peptides correlate with a higher 
probability of HF in patients with dyspnea (22, 23). However, studies have shown that there is 
an inverse relationship between BNP / NT-proBNP levels and body weight making test results 
more complex to assess in the obese patient (24, 25). A review article published in 2014 (25) 
recommends adjusting cut-off points for BNP-levels according to body weight but that with 
respect to NT-proBNP it should be enough to adjust cut-off points for age as recommended in 
the general population. Here, body weight does not critically affect the specificity or 
sensitivity of the test. 
 
As the prevalence of obesity continues to rise and the incidence of HF increases in younger 
individuals, the patient group consisting of young, obese patients with HF is of interest for 
further studies. Data from the Swedish National Patient Registry (NPR) regarding diagnoses 
is often used in population-based studies, and accordingly it is of interest to know to what 
extent these diagnoses conform to standard diagnostic guidelines.  
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3. Aim / Research question 
3.1. Aim 
The aim of this study was to investigate the validity of HF diagnoses in the Swedish national 
patient registry (NPR) in patients with a concurrent obesity diagnosis using information from 
medical records.  
 
3.2. Research question 
What is the validity of HF diagnoses in the Swedish national patient registry in patients with 
concurrent obesity? 
 
4. Material and methods 
4.1. Participants 
In this study, the study population was derived from consecutive patients with an obesity 
diagnosis (ICD10 E65 – E66) recorded at the Obesity care unit (2000 – 2006) or at the 
Regional Obesity Center at Sahlgrenska University hospital (2007 – 2017) identified from the 
register of medical records of the Västra Götaland Region (VGR) in Sweden (n=8,202). From 
these 8,202 patients, all patients with an additional diagnosis of HF were selected using 
International Classification of Disease codes for HF (ICD10 I50.0 – I50.9).  The study 
population thus identified consisted of 77 patients, all with a diagnosis of obesity and a 
concurrent diagnosis of HF.  
 
From these 77 patients the medical records in the digital record system of the VGR (Melior) 
were reviewed. 45 of the patients went through a validation of the HF diagnosis (Figure 1). 
Patients were excluded in cases where a validation could not be made. This could be due to 
the first diagnosis of HF not being recorded at Sahlgrenska university hospital or Kungälv 
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hospital, but at another hospital or in primary care, or because the patient was diagnosed 
before the era of digital patient records, with subsequent loss of information. Patients were 
also excluded if the record was blocked by the patient and therefore could not be scrutinized. 
2 patients were excluded because the patient records did not contain enough information for 
the diagnosis to be validated.  
  
Figure 1. Exclusion criteria  
 
Flowchart showing exclusion of patients where a validation of the HF diagnosis could not be 
made. 
 
4.2. Data collection 
Information from patient visits at inpatient- or outpatient clinics in western Sweden are 
recorded in the digital record system (Melior). All principal and contributory diagnoses are 
then sent to and registered in the Swedish National Patient registry (NPR), which includes 
records of all hospitalizations (inpatient registry) and specialist outpatient visits (outpatient 
registry, since 2001). The registry has 100 % coverage of discharges from Swedish hospitals 
77 patients 
First diagnosis of HF not 
doccumented in Melior 
n = 16 
No access to medical journal 
n = 3 
First HF diagnosis made at other hospital 
or in primary care 
n = 11 
Not enough information to complete 
validation 
n = 2 
45 patients 
who underwent validation of HF 
diagnosis 
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since 1987 and onwards. Data regarding diagnoses in the NPR are frequently used for 
administrative or research purposes. A validation of the Swedish national inpatient register 
(IPR) has shown that the positive predictive value (PPV) of diagnoses is 85-95 % for most 
diagnoses (26).  
 
Information on each patient was obtained using medical records in the digital system Melior. 
A form designed for the purpose of this study was used to document information regarding 
the obesity and the HF diagnosis (Appendix). The first diagnosis of HF according to ICD-10 
codes in each patient journal was validated. 
 
Patient history and signs of heart failure 
In cases where the patient received their HF diagnosis during a hospitalization, information 
regarding signs and symptoms was taken from the entire hospitalization period. In cases 
where the patient received their diagnosis at an outpatient clinic, information from the visit to 
the clinic was primarily used. If no physical examination was performed and / or if the patient 
history was incomplete, this information was taken from the clinical unit that referred the 
patient to the clinic via the referral note. 
 
Echocardiography 
The most recent echocardiography report was analysed. If an echocardiography was not 
performed at the time of HF diagnosis, echocardiographic examinations from the time with 
the most obvious signs of HF previous to the diagnosis were used. An echocardiography 
report with a left ventricular ejection fraction (LVEF) < 50 % was considered pathological 
and as objective evidence of HF. In all cases with LVEF > 50 %, the test results were 
interpreted by an experienced cardiologist. 
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A pathological echocardiography report fulfilling HF criteria, magnetic resonance imaging 
(MRI) of the heart, left ventricular (LV) angiography and scintigraphy of the heart were all 
considered as objective evidence of HF. As in the case of echocardiography results, MRI, LV 
angiography and scintigraphy results were considered as showing objective evidence of HF if 
LVEF was < 50 %. If LVEF was > 50 %, the results were interpreted by an experienced 
cardiologist. 
 
Electrocardiography (ECG) 
In the case of hospitalizations, the first ECG, most often from the emergency care department 
was used. If the diagnosis was recorded from an outpatient visit, the most recent ECG report 
was used. An ECG was considered pathological if at least one of the following was present; 
rhythm other than sinus or AV-block I, QRS-duration > 100 ms or pathological Q waves.  
 
Chest X-ray 
If multiple chest X-rays were performed before the diagnosis of HF, the most recent 
examination was used. Finds considered signs of HF were: pulmonary congestion, widening 
of the pulmonary vessels, edema, redistribution and cardiomegaly.  
 
Natriuretic peptides 
Both the latest value of NT- proBNP obtained and the highest value was recorded. Reference 
values from the review article by C.Madamanchi et al. (25) were used.  
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4.3. European Society of Cardiology guidelines 
New guidelines for the diagnosis and treatment of HF were published by ESC during the time 
when the patients were diagnosed with HF: in 1995, 2001, 2005, 2008, 2012 and 2016. In this 
study it was assumed that new guidelines would be implemented in clinical work the year 
after they were published. This means that the 2001 guidelines would be in clinical use from 
2002, hence the validation of the diagnoses made in 2002 was made according to the 
guidelines published in 2001, etc. 
 
Table 1. Diagnostic assessments supporting or opposing the heart failure diagnosis from 
the different ESC guidelines between years 1995 – 2008.  
 1995 2001 2005 2008 
 
 
Supports if 
present/ 
Opposes if 
normal or absent 
Supports if 
present/ 
Opposes if 
normal or absent 
Supports if 
present/ 
Opposes if 
normal or absent 
Supports if 
present/ Opposes 
if normal or 
absent 
Appropriate 
symptoms 
+++*/--- +++*/-- +++*/--- ++*/-- 
Appropriate 
signs 
+++/- +++/- +++/- ++*/- 
Response to 
treatment 
+++/--- +++/--- +++/--- +++/-- 
Pathological 
ECG 
/--- /--- /--- ++/-- 
Cardiac 
dysfunction on 
imaging 
+++*/--- +++*/--- +++*/--- +++**/-- 
Chest X- ray +/- +/- +/- +++/- 
Natriuretic 
peptides 
n/a + (if elevated)  
/--- 
+ (if elevated)  
/--- 
+++ (if elevated)  
/--- 
Abbreviations: +/- of some importance, ++/-- of particular/ considerable importance, +++/--- 
of major importance, ECG; electrocardiogram, ESC; European society of cardiology. * 
Necessary for definite diagnosis. ** Considered an objective evidence of cardiac dysfunction. 
n/a; Not applicable. This assessment is adapted from the heart failure diagnostic guidelines 
edited by the ESC in 1995, 2001, 2005 and 2008. This adaptation was made by 
Schaufelberger M et al. (unpublished). 
 
The importance of different diagnostic tools for the diagnosis of HF between years 1995 – 
2008 is described in Table 1. The changes in diagnostic recommendations included the 
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addition of a mandatory criterion of clinical signs of HF in the guidelines published 2008. The 
guidelines of 2012 state the signs-criterion as necessary for HF diagnosis as in the guidelines 
of 2008, however with the footnote that signs may be missing in patients with early HF or 
when treated with diuretics (Table 2). From 2012 the definition of HF was extended to 
defining HF with preserved ejection fraction (HF-PEF) and HF with reduced ejection fraction 
(HF-REF) as two different entities based on echocardiography results, hence making 
echocardiography an obligatory examination for the diagnosis to be made. This is also the 
case in the guidelines of 2016, where the definition of HF is further extended to HF with mid-
range EF (HFmrEF) for patients with an EF between 40 - 49 % (Figure 2).  
 
Table 2. The definition of HF according to the ESC guidelines of 2012 (16).  
The diagnosis of HF-REF requires three conditions to be satisfied: 
1. Symptoms typical of HF 
2. Signs typical of HF* 
3. Reduced LVEF 
The diagnosis of HF-PEF requires four conditions to be satisfied: 
1. Symptoms typical of HF 
2. Signs typical of HF* 
3. Normal or only mildly reduced LVEF and LV not dilated 
       4. Relevant structural heart disease (LV hypertrophy / LA enlargement) and / or diastolic 
dysfunction. 
Abbreviations: LA = left atrial; LV = left ventricular; LVEF = left ventricular ejection 
fraction. 
*Signs may not be present in the early stages of HF (especially in HF-PEF) and in patients 
treated with diuretics. 
 
Figure 2. The definition of HF according to the ESC guidelines of 2016 (17). 
 
conduction can also cause HF (and more than one abnormality is of-
ten present). Identification of the underlying cardiac problem is cru-
cial for therapeutic reasons, as the precise pathology determines the
specific treatment used (e.g. valve repair or replacement for valvular
disease, specific pharmacological therapy for HF with reduced EF,
reduction of heart rate in tachycardiomyopathy, etc).
3.2 Terminology
3.2.1 Heart failure with preserved, mid-range and reduced
ejection fraction
The main terminology used to describe HF is historical and is based
on measurement of the LVEF. HF comprises a wid range of pa-
tients, from those with normal LVEF [typically considered as
≥50%; HF with preserved EF (HFpEF)] to those with reduced
LVEF [typically considered as ,40%; HF with reduced EF (HFrEF)]
(Table 3.1). Patients with an LVEF in the range of 40–49% represent
a ‘grey area’, which we now define as HFmrEF (Table 3.1). Differen-
tiation of patients with HF based on LVEF is important due to
different underlying aetiologies, demographics, co-morbidities and
response to therapies.6 Most clinical trials published after 1990 se-
lect d patients based n LVE [usually measured using ec ocardiog-
raphy, a radionuclide technique or cardiac magnetic resonance
(CMR)], and it is only in patients with HFrEF that therapies have
been shown to reduce both morbidity and mortality.
The diagnosis of HFpEF is more challenging than the diagnosis of
HFrEF. Patients with HFpEF generally do not have a dilated LV, but
inst a often have an increase in LV wall thickness and/or increased
left atrial (LA) size as a sign of increased filling pressures. Most have
additional ‘evidence’ of impaired LV filling or suction capacity, also
classified as dia tolic dysfunction, which is generally accepted as
the likely cause of HF in these patients (hence the term ‘diastolic
HF’). However, most patients with HFrEF (previously referred to
as ‘systolic HF’) also have diastolic dysfunction, and subtle abnormal-
ities of systolic function have been shown in patients with HFpEF.
Hence the preference for stating preserved or reduced LVEF over
preserved or reduced ‘systolic function’.
In previous guidelines it was acknowledged that a grey area exists
between HFrEF and HFpEF.7 These patients have an LVEF that
ranges from 40 to 49%, hence the termHFmrEF. Identifying HFmrEF
as separate group will stimulate research into the underlying
characteristics, pathophysiology and treatment of this group of pa-
tients. Patients with HFmrEF most probably have primarily mild sys-
tolic dysfunction, but with features of diastolic dysfunction
(Table 3.1).
Patients without detectable LV myocardial disease may have
other cardiovascular causes for HF (e.g. pulmonary hypertension,
valvular heart disease, etc.). Patients with non-cardiovascular path-
ologies (e.g. anaemia, pulmonary, renal or hepatic disease) may have
symptoms similar or identical to those of HF and each may compli-
cate or exacerbate the HF syndrome.
3.2.2 Terminology related to the time course of heart
failure
In these guidelines, the termHF is used to describe the symptomatic
syndrome, graded according to the New York Heart Association
(NYHA) functional classification (see Section 3.2.3 and Web
Table 3.2), although a patient can be rendered asymptomatic by
treatment. In these guidelines, a patient who has never exhibited
the typical symptoms and/or signs of HF and with a reduced LVEF
is described as having asymptomatic LV systolic dysfunction. Patients
who have had HF for om time are often said to have ‘chronic HF’.
A treated patient with symptoms and signs that have remained gen-
erally unchanged for at least 1 month is said to be ‘stable’. If chronic
stable HF deteriorates, the patient may be described as ‘decompen-
sated’ and this may happen suddenly or slowly, often leading to hos-
pital admission, an event of considerable prognostic importance.
New-onset (‘de novo’) HF may also present acutely, for example,
as a consequence of acute myocardial infarction (AMI), or in a sub-
acute (gradual) fashion, for example, in patients with a dilated cardio-
myopathy (DCM), who often have symptoms for weeks or months
before the diagnosis becomes clear. Although symptoms and signs
of HF may resolve, the underlying cardiac dysfunction may not, and
patients remain at the risk of recurrent ‘decompensation’.
Occasionally, however, a patient may have HF due to a problem
that resolves completely (e.g. acute viral myocarditis, takotsubo car-
diomyopathy or tachycardiomyopathy). Other patie ts, particularly
those with ‘idiopathic’ DCM, may also show substantial or even
complete recovery of LV systolic function with modern disease-
modifying therapy [including angiotensin-converting enzyme inhibi-
tor (ACEI), beta-blocker, mineralocorticoid receptor antagonist
Table 3.1 Definition of heart failure with preserved (HFpEF), mid-range (HFmrEF) and reduced ejection fraction
(HF EF)
BNP ¼ B-type natriuretic peptide; HF ¼ heart failure; HFmrEF ¼ heart failure with mid-range ejection fraction; HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼
heart failure with reduced ejection fraction; LAE ¼ left atrial enlargement; LVEF ¼ left ventricular ejection fraction; LVH ¼ left ventricular hypertrophy; NT-proBNP ¼ N-terminal
pro-B type natriuretic peptide.
aSigns may not be present in the early stages of HF (especially in HFpEF) and in patients treated with diuretics.
bBNP.35 pg/ml and/or NT-proBNP.125 pg/mL.
ESC Guidelines 2137
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4.4. Validation of the diagnosis 
The HF diagnosis of all patients underwent primary validation by a medical student (KA) and 
was classified as definite, probable or miscoded according to the relevant ESC guidelines. In 
cases with uncertainty as to the validity of the diagnosis, the validation was made by an 
experienced cardiologist. In all cases where the patient presented with symptoms and / or 
signs of HF accompanied by an echocardiographic examination with LVEF > 50 %, the 
validation was also made by an experienced cardiologist. 5 randomly selected patients went 
through a second validation by an internist at the department of medicine to evaluate inter-
observer accuracy.  
 
Typically, a diagnosis validated as definite would have to fulfil the symptoms and (according 
to the ESC guidelines of 2008 and later) signs criterion of HF accompanied by an 
echocardiography report showing objective evidence of HF. The diagnosis would be further 
supported by a chest X-ray showing signs of HF and a pathological ECG even if these were 
not necessary for the diagnosis to be classified as definite. A probable diagnosis would 
typically fulfil the symptoms- and (2008) signs criterion but lack echocardiography results or 
other objective evidence of HF. A miscoded diagnosis would show symptoms or signs of HF 
without objective evidence, with an echocardiography report lacking signs of HF. The 
diagnosis would be further contradicted by a normal ECG and / or chest X-ray without signs 
of HF. A diagnosis would also be classified as miscoded if neither symptoms nor clinical 
signs (2008) were present.  
 
5. Ethics 
This study was performed without contact with or informed consent from the patients 
involved, with the data presented in such a way that it was not possible to identify individual 
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patients. No biological material was collected from participants. The medical records were 
handled using the hospitals digital system, Melior and no physical copies of the patient 
journals were saved. The study was approved by the Regional Ethics Review board in 
Gothenburg 2017-03-22, registration number: 171-17.  
 
6. Data collection procedures 
Personal identification numbers were acquired for all patients who received an obesity 
diagnosis made at the obesity care unit (2000-2006) or at the Regional Obesity Centre (2007-
2017). From these patients, all patients with a concurrent HF diagnosis were selected using 
international classification of disease codes (ICD10) E66 and E65 for obesity and I50 for HF. 
The personal identification numbers of these patients were transferred to an Excel file and 
were assigned an ID number used throughout the study. The key document containing 
personal identification numbers and corresponding ID numbers of the participants was stored 
in one copy on a hard drive at Sahlgrenska university hospital.  
 
Information regarding the HF diagnosis was extracted from the medical records of each 
patient using a form especially designed for this study (Appendix 1) and was then transferred 
into an Excel document. After excluding patients where the HF diagnosis could not be 
validated (Figure 1), the data was transformed into an SPSS file.  All statistical analyses were 
made using SPSS. Descriptive statistics were used to describe baseline characteristics, 
percentages and to calculate mean and median values and standard deviations (SD). 
 
To check for inter observer-accuracy; five patient records were accessed in order to go 
through a second validation of the HF diagnosis performed by an internist. These patients 
were randomly selected using the RANDBETWEEN function in Excel.  
  16 
7. Results 
7.1. Study population 
8202 patients received an obesity diagnosis code at the regional obesity center of Sahlgrenska 
university hospital during the period 2000 to 2017. Of these patients 77 were diagnosed with 
HF (before or after the obesity diagnosis) before 2017. After exclusions, the HF diagnoses of 
45 patients were validated (Figure 1). Baseline characteristics of patients are shown in Table 
3.  
Table 3. Baseline characteristics 
* Value taken from time of first visit to obesity center. This could be before or after HF 
diagnosis.  
 
Characteristic Median Number of patients  
n (%) 
Age at HF diagnosis (years)   
- Median (min - max) 58 (35 – 77)  
Women  15 (33.3) 
Men  30 (66.7) 
BMI at obesity diagnosis 
(kg/m2)* 
  
- Median (min - max) 41.6 (29.5 – 61.0)  
- Missing values  10 (22.2) 
Hospital    
- Sahlgrenska hospital  28 (62.2) 
- Östra hospital  10 (22.2) 
- Mölndal hospital  3 (6.67) 
- Kungälv hospital  4 (8.89) 
Diagnosis validated from   
- inpatient clinic  35 (77.8) 
- outpatient clinic  10 (22.2) 
Validated according to   
- ESC guidelines of 1995  5 (11.1) 
- ESC guidelines of 2001  12 (26.7) 
- ESC guidelines of 2005  11 (24.4) 
- ESC guidelines of 2008  10 (22.2) 
- ESC guidelines of 2012  7 (15.6) 
- ESC guidelines of 2016  0 (0) 
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7.2. Validity 
A total of 29 cases (64.4 %) of the HF diagnoses were classified as definite, 15 (33.3 %) as 
probable and 1 (2.2 %) as miscoded (Table 4). The proportion of definite cases increased over 
time with 20.0 % in 1995, 58.3 % in 2001, 63.6 % in 2005, 70.0 % in 2008 and 100 % in 
2012. There were no diagnoses of HF made during 2017 validated in this study and 
accordingly no diagnoses were validated according to the guidelines of 2016. 
 
Table 4. Validity of HF diagnosis and year of ESC guidelines. 
ESC guidelines Total 
n 
Definite 
n (%) 
Probable 
n (%) 
Miscoded 
n (%) 
1995 5 1 (20.0) 4 (80.0) 0  
2001 12 7 (58.3) 5 (41.6) 0  
2005 11 7 (63.6) 4 (36.4) 0  
2008 10 7 (70.0) 2 (20.0) 1 (10.0) 
2012 7 7 (100) 0 0  
2016 0    
Total validity 45 29 (64.4) 15 (33.3) 1 (2.2) 
 
There were 35 diagnoses made at inpatient clinics and 10 diagnoses at outpatient clinics 
(Table 5). The proportion of definite diagnoses was 60 % and 80 % respectively.  
 
Table 5. Validity of HF diagnosis in the inpatient- and outpatient clinic. 
 Total 
n (%) 
Definite  
n (%) 
Probable 
n (%) 
Miscoded 
n (%) 
Inpatient clinic 35 (100) 21 (60.0) 13 (37.1) 1 (2.9) 
Outpatient 
clinic 
10 (100) 8 (80.0) 2 (20.0) 0 (0) 
 
 
7.3. Inter-observer accuracy 
5 randomly selected patients went through a secondary validation by an internist at a medicine 
clinic to check for inter-observer accuracy. Four of these were validated in the same way as in 
the primary validation, three as definite and one as probable HF. One was given to an 
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experienced cardiologist for further evaluation, a decision made by both the medical student 
in the primary validation and by the internist performing the secondary validation. This 
diagnosis was then classified as definite. 
 
8. Discussion with Conclusions and Implications 
8.1. Results in relation to existing literature 
In this study, 64.4 % of cases were classified as definite cases of HF, 33.3 % as probable and 
2.2 % as miscoded.  
 
In the study by Ingelsson et al (20) which was performed in a much earlier setting 82 % of 
317 HF diagnoses in the IPR were classified as definite, 16 % as questionable and 2 % as 
miscoded. For the diagnosis to be classified as definite, the presence of symptoms, signs and 
objective evidence of HF was required. Objective evidence was preferably from an 
echocardiography but could also be from an electrocardiography or from a chest X-ray in 
cases where an echocardiography was not performed. In our study, an X-ray showing signs of 
HF and a pathological electrocardiography supported the HF diagnosis but were not 
considered objective evidence. Hence it is likely that some cases classified as probable in our 
study would be classified as definite in the study by Ingelsson et al.  
 
In a recent study published in 2017, the medical records of 712 patients diagnosed with HF 
after hospitalization at one of 14 different hospitals in Texas, USA, were examined (27). 19 % 
of these diagnoses were classified as having low probability, 33 % as medium probability and 
48 % as high probability. The validation was made according to a protocol based on recent 
American and European guidelines for the diagnosis of HF. According to the protocol of the 
study, raised natriuretic peptides, echocardiography, chest x-ray, symptoms and signs were all 
  19 
needed for the diagnosis to be classified as having high probability. These demands are 
stricter than those of our study and it is therefore likely that part of the diagnoses classified as 
definite in our study would be classified as having medium probability in the study by Carey 
SA et al. This may partly explain why our results indicate a higher validity of the HF 
diagnosis. 
 
In a study by Schaufelberger et al (manuscript), 62.3 % of 965 patients hospitalized at 
Sahlgrenska university with a diagnosis of HF were classified as definite, 32.1 % as probable 
and 5.6 % as miscoded. In this study the validation was made according to the ESC guidelines 
using a similar protocol as the one used in our study. The results of the two studies are 
similar, which would indicate that the validity of HF diagnosis is not lower in obese patients 
compared to in the general population.   
 
8.2. Group characteristics 
Table 2 shows baseline characteristics of the patient group. The median age for HF diagnosis 
was 58 years. This can be compared to the median age of HF in the general population, which 
is between 70 – 76 years (28, 29). That the age of the study population was generally low at 
the time of diagnosis may affect the results of the validation. It is possible that younger 
patients are more extensively examined, and that the validity of the diagnosis is therefore 
higher in younger age groups. The design and size of this study is not appropriate to answer 
this question. In our study, only 33.3 % of patients were women. Due to the small size of this 
study, it is possible that this is only due to chance but a similar distribution between sexes is 
found in other studies looking at HF patients in younger age groups (3). An explanation to 
this may be that women have a lower prevalence of HF (1) and are diagnosed with HF later 
than men (28).    
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8.3. Comments on specific cases 
It was noted during the acquisition of data from the patient journals that the level of detail in 
documentation was generally lower in journal notes from outpatient clinics than in those from 
inpatient clinics. In six cases, no record of a physical examination was found in the patient 
journal. Four of these patients were diagnosed with HF at an outpatient clinic. Since only 10 
diagnoses made at outpatient clinics were validated, these 4 constitute a substantial portion. 
However, 3 of these cases could be classified as definite even without recorded signs of HF. 
Two diagnoses were from the period before 2008 when the signs criterion was added to the 
ESC guidelines and in one case, diagnosed in 2014 the patient was taking medications 
(candesartan) which could potentially mask the signs of HF and was therefore classified as 
definite in a second validation by an experienced cardiologist. Even if it is unlikely that the 
fact that the records from outpatient clinics were shorter and less detailed would have affected 
the results of this study, it is important to note this in the planning of future validation studies.  
 
It is also worth commenting the one case of HF validated as miscoded in this study. This 
patient showed no symptoms of HF and an examination showed no signs of HF. There was an 
echocardiography performed a few months previous to the diagnosis showing reduced LVEF, 
which, in the absence of symptoms, was not considered sufficient to validate the diagnosis as 
probable. This decision was taken both in the primary validation by the medical student and in 
a secondary validation by an experienced cardiologist.   
 
8.4. ESC guidelines of 2008 
When validating in accordance to the ESC guidelines, the guidelines published in 2008 stand 
out in several ways. As previously mentioned, in 2008 clinical signs of HF were added as a 
mandatory criterion for the diagnosis. Regarding the criterion of objective evidence of HF this 
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was broadened to include cardiomegaly, third heart sound, cardiac murmurs, raised natriuretic 
peptide concentration or abnormality on the echocardiogram. This means that in contrast to 
previous and later years, it was enough for a patient to experience symptoms of HF, show 
signs of HF and for example show cardiomegaly on chest X-ray for the diagnosis to be 
classified as definite, where in previous and subsequent years cardiac dysfunction on imaging 
is needed for a definite diagnosis. A total of 10 cases in this study (22.2 %) were validated 
according to the ESC guidelines of 2008. 
 
8.5. Limitations of the study 
The major limitation of this study is the limited number of patients. With only 45 validated 
diagnoses we cannot draw definitive conclusions from the data. However, the results can give 
an indication as to whether it would be relevant to do further studies in this area.  
 
As this study was a retrospective review of medical records, we only had access to 
information documented in these. The evaluation of the diagnosis depended heavily on 
accurate and descriptive medical notes and we could never presume to have access to the 
same information as the diagnosing clinician. Although the validation was made according to 
the ESC guidelines, a clinical judgement was needed by a medical student or by a cardiologist 
and the classification of the diagnoses cannot be considered completely objective. However, 
when checking for inter-observer accuracy the five diagnoses that went through a secondary 
validation were validated in the same way as in the primary validation. This indicates that 
inter observer accuracy was high. 
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8.6. Conclusion 
In conclusion, this study indicates that the validity of HF diagnosis in the NPR among patients 
with obesity is comparable to the validity in patients without obesity. However, due to the size 
of the study population, further and larger studies are needed to verify these results.   
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9. Populärvetenskaplig sammanfattning på svenska 
Hjärtsvikt är en allvarlig sjukdom med dålig prognos. Ungefär 2 % av den svenska 
befolkningen lider av hjärtsvikt och man har sedan 1990-talet sett en minskning av antalet nya 
hjärtsviktsfall, men att hjärtsvikt hos unga ökar. Hjärtsvikt har flera riskfaktorer såsom 
hjärtinfarkt, högt blodtryck och vissa hjärtfel, och man har i tidigare studier visat att fetma är 
en stark riskfaktor. Fetma, definierat som ett Body Mass Index (BMI) över 30 kg/m2, är ett 
ökande hälsoproblem i befolkningen och nästan dubbelt så många individer världen över har 
fetma idag jämfört med på 1980-talet.  
Det finns inget enskilt test som kan utföras för att ställa en hjärtsviktsdiagnos, utan diagnosen 
är beroende av att patienten uppvisar symptom och fynd vid en kroppsundersökning. Typiska 
symptom är underbenssvullnad, andfåddhet och minskad kondition. Dessa symptom finns 
även hos patienter med fetma vilket kan göra det svårare att ställa en hjärtsviktsdiagnos. 
European Society of Cardiology (ESC) publicerar regelbundet riktlinjer för behandling och 
diagnossättning av hjärtsvikt och tidigare studier har visat att hjärtsviktsdiagnoser i svenska 
patientregister stämmer väl överens med dessa riktlinjer. 
Syftet med denna studie var att undersöka om patienter med fetma som även har en 
hjärtsviktsdiagnos verkligen har hjärtsvikt enligt ESC:s riktlinjer. Detta gjordes genom att 
granska patientjournaler från alla patienter som fått en fetmadiagnos på Västra 
Götalandsregionens regionala obesitascentrum mellan år 2000 – 2017 som även fått en 
hjärtsviktsdiagnos innan år 2017. Ett speciellt framtaget formulär användes för att samla 
information från det första tillfället med en hjärtsviktsdiagnos i patientjournalen och varje 
diagnos bedömdes sedan som säker, trolig eller felaktig enligt ESC:s riktlinjer. Sammanlagt 
undersöktes hjärtsviktsdiagnoser hos 45 patienter.  
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Av de 45 hjärtsviktsdiagnoser som undersöktes bedömdes 64 % som säker hjärtsvikt, 33 % 
som trolig hjärtsvikt och 2 % som felaktiga. Detta resultat är jämförbart med resultaten från 
tidigare studier som undersökt hjärtsviktsdiagnoser hos befolkningen i stort. Resultaten från 
denna studie tyder på att hjärtsviktsdiagnoser hos patienter med fetma är ungefär lika 
välställda som hos resten av befolkningen men studiens storlek gör att fler, större studier 
behövs för att säkerställa resultaten.  
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12. Appendix  
12.1. Form for extracting data from patient records 
	
PATIENTFORMULÄR obesitas 
1. Id: 
 
 Granskare:  
2. Valideringsdatum: 
(ÅÅ-MM-DD) 
   
 
 
FETMADIAGNOS 
3. Fetmadiagnosdatum: 
    (inskrivning på 
    obesitasmottagning) 
    (ÅÅ-MM-DD) 
 
4. Diagnoskod obesitasmottagning (ICD10) 
E65 Lokaliserad fetma 
E66.0 Extrem fetma orsakad av kaloriöverskott 
E66.01 Annan fetma orsakad av kaloriöverskott    
E66.1 Läkemedelsutlöst fetma 
E66.2 Extrem fetma m. alevolär hypoventliation   
E66.8 Annan specificerad fetma/ sjuklig fetma 
E66.9 Fetma, ospecificerad 
 
 
5.a Diagnossättning 
Huvuddiagnos (1) 
Bidragande diagnos (2) 
 5.b Om bidragande 
diagnos, 
huvuddiagnos: 
 
6.a Ev. känd obesitas sedan:   
(Journalanteckning/  
diagnoskod) 
(ÅÅ-MM-DD) 
 
6.b Sjukhus: 
(Om tidigare fetmadiagnos) 
SU (öppenvård) (1)                            SU (slutenvård) (2)                            
Slutenvård inom VGR (ej SU) (3)     Öppenvård inom VGR (ej SU) (4) 
 
6.c Mottagning: 
   (Fritext)  
 
 
7. Vikt, kg: 
   (en decimal) 
 
 
kg 
8. Längd, cm:  
cm 
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9. Vikt inom 1 år 
innan diagnos: 
   (en decimal) 
 
 
kg 
10. Vikt inom 1 år efter 
diagnos: 
(en decimal) 
 
 
kg 
11.a Uppgifter om 
bukfetma 
   (Kvinnor >88, män 
>102cm) 
Ja (1) 
Nej (0) 
Okänt (2) 
 11.b Om ja, hur? 
Mätning (1)  
Journalanteckning (2) 
 
 
12. Önskemål om 
fetmakirurgi 
Ja (1) 
Nej (0) 
Ej lämpligt enl. läkare (2) 
Okänt (3) 
 13. Genomgått 
fetmakirurgi 
Ja (1) 
Nej (0) 
Okänt (2) 
 
14.a Tidigare seriöst 
försök att gå ner i 
vikt  
(ex. kostförändring/ 
motion) 
Ja (1) 
Nej (0) 
Okänt (2) 
 14.b Om ja, hur? 
(Fritext) 
 
BAKGRUNDSINFORMATION vid index* 
15. Kön 
Man (0)  
Kvinna (1) 
 
 16. Födelseår och 
månad: 
(ÅÅ-MM) 
 
17.a Civilstånd 
Singel (1) 
Gift/ sambo (2) 
Särbo (3) 
Skild (4) 
Änka/änkling (5) 
Annat (6) 
 
 17.b Om annat, vad: 
(Fritext) 
 
18. Härkomst/ etnicitet 
Svensk (1)       Nordisk, ej Sverige (2) 
Europeisk (3)  Utom Europa (4) 
Okänt (5) 
 
 19. Antal personer i 
hushåll 
 
 
20.a Avliden (idag) 
Ja (1) 
Nej (0) 
Okänt (2) 
 20.b Om ja, datum: 
(ÅÅ-MM-DD) 
 
 
MÄTVÄRDEN vid index* 
21. Systoliskt 
blodtryck: 
 
 
mmHg 
22. Diastoliskt 
blodtryck: 
 
 
mmHg 
	
 
  
 
30 
 
23. LDL: 
 
 
 
mmol/L 
 
 
24. HDL: 
 
 
mmol/L 
25. TG: 
 
 
 
 
mmol/L 
 
26. S-kolesterol/ 
plasmakolesterol: 
 
 
mmol/L 
 
 
27. HbA1c:  
(ange enhet) 
mmol/mol 
eller % 
 
 
* Index: fetmadiagnos. Använde värden närmst i tiden till inskrivning på obesitasmottagning  
 
FETMAKIRURGI 
28. Operationskod: 
(Åtgärdskod, efter 1997) 
JDF00 Gastroplastik 
JDF01 Laparoskopisk gastroplastik 
JDF10 Gastric bypass 
JDF11 Laparoskopisk gastric bypass 
JDF20 Magsäcksbandning  
JDF21Laparoskopisk 
magsäcksbandning 
JFD03 Duodenal bypass 
JFD04 Laparoskopisk duodenal 
bypass  
Okänt (0) 
 
29. Ålder (i år) vid 
fetmakirurgi: 
 30. Datum för 
fetmakirurgi: 
(ÅÅ-MM-DD) 
 
 
31. Sjukhus: 
(Fritext) 
 
 
32. Klinik: 
(Fritext) 
 
 
33. Vikt, kg: 
(en decimal) 
 
 
 
kg 
34. Vikt 1 år 
efter operation 
(en decimal) 
 
 
 
kg 
Läkemedel 
35.a A10 Diabetesmedel 
Ja (1) 
Nej (0) 
 
 
 
    35.b Om ja, kod(er):  
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36.a C kapitlet 
Hjärta och 
kretslopp 
Ja (1) 
Nej (0) 
 
 
36.b Om ja, kod(er):  
 
37.a N05 
Neuroleptika, 
lugnande medel och 
sömnmedel 
Ja (1) 
Nej (0) 
 
 
37.b Om ja, kod(er):  
38.a N06 
Psykoanaleptika 
Ja (1) 
Nej (0) 
 
38.b Om ja, kod(er):  
 
ÖVRIGA SJUKDOMAR 
 
39.a Diabetes 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
     Okänt (2) 
 
39.b Om ja, år: (ÅÅ) 
 39.c Om ja, typ: 
Typ I (1) 
Typ II (2) 
Graviditetsdiabetes (3) 
Okänt (4) 
 
40.a Diabetesbehandling 
(Diagnos i journaltext) 
Ingen behandling (1) 
Kost (2) 
Kost + insulin (3) 
Kost + tablett (4) 
Kost + tablett + insulin 
(5) 
 
 
40.b Annan 
injektionsbehandling 
Ja (1) 
Nej (0) 
 
 
41.a Hypertoni 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
41.b Om ja, år: (ÅÅ) 
 41.c Behandling för 
hypertoni 
Ja (1) 
Nej (0) 
 
 
41.d om ja, hur? 
(Fritext) 
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42.a Ischemisk 
hjärtsjukdom 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
42.b Om ja, år: (ÅÅ)  
 43.a Kardimyopatier 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
43.b Om ja, år: (ÅÅ)  
 
44.a Förmaksflimmer 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
44.b Om ja, år: (ÅÅ)  
 45.a Hjärtsvikt 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
45.b Om ja, år: (ÅÅ) 
 
46.a KOL eller astma 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
46.b Om ja, år: (ÅÅ) 
 
 47.a Stroke 
(Diagnos i journaltext) 
Ja (1) 
Nej (0)  
 
47.b Om ja, år:(ÅÅ) 
 
 
48.a Obstruktiv sömnapné, ev. CPAP-behandling 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
48.b Om ja, år: (ÅÅ)  
 
49.a Lungemboli eller DVT 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
49.b Om ja, år: (ÅÅ)  
 
50.a Kronisk psykisk sjukdom 
(Diagnos i journaltext) 
Ja (1) 
Nej (2) 
 
 
50.b Om ja, år: (ÅÅ)  
 
51.a Allvarlig ätstörning 
(Uppgift om anorexi/ bulimi) 
Anorexi(1) 
Bulimi (2) 
 Ingen (3)  
 
51.b Om ja, år: (ÅÅ)  
 
 
52.a Hyperthyreos 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
52.b Om ja, år: (ÅÅ) 
 
53.a Hypothyreos 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
53.b Om ja, år: (ÅÅ) 
 
 
54.a Inflammatorisk 
systemsjukdom 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
54.b Om ja, år: (ÅÅ) 
 
 55.a Njurinsufficiens 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
55.b Om ja, år: (ÅÅ) 
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55.c Serum kreatinin 
(om relevant) 
 
 
 
                               µmol/L 
56.a Cancersjukdom 
de senaste 5 åren 
Ja (1) 
Nej (0) 
 
56.b Om ja, år: (ÅÅ) 
 
 
56.c Om ja, vilken: 
(Fritext) 
 
 
 
 
 
57. Rökare 
Aldrig (1) 
Aktiv (2) 
Ex-rökare (Slutat minst tre månader) (3) 
Okänt (4) 
 
 
58.a Missbruk  
(Ex. alkohol, droger) 
Ja (1) 
Nej (0) 
 
 58.b Om ja, vilket? 
(Fritext) 
 
59. Annan sjukdom 
eller kommentar: 
(Fritext) 
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PATIENTFORMULÄR Hjärtsvikt 
Extra granskare: 
(Vid svårtolkade värden) 
   
60. 
Valideringsdatum: 
(ÅÅ-MM-DD) 
 61. Diagnosdatum, 
hjärtsvikt: 
(ÅÅ-MM-DD) 
 
 
 
62. Sjukhus och 
klinik för epikris: 
 (Fritext) 
 
63. Diagnossättning 
Huvuddiagnos (1)  
Bidiagnos (2) 
 64. Ålder (i år) vid 
hjärtsvikt: 
(vid epikris) 
 
65.a Avliden: 
(Idag) 
Ja (1) 
Nej (0) 
 
65.b Om ja, datum:       
(ÅÅ-MM-DD)  
    
Anamnestiska uppgifter* 
66. Trötthet: 
Ja (1) 
Nej (0) 
Okänt (2) 
67. Viktuppgång: 
Ja (1) 
Nej (0) 
Okänt (2) 
68. Bensvullnad: 
Ja (1) 
Nej (0) 
Okänt (2) 
69. Dysapné: 
Ja (1) 
Nej (0) 
Okänt (2) 
70. Hosta: 
Ja (1) 
Nej (0) 
Okänt (2) 
71. Ortopné:  
Ja (1) 
Nej (0) 
Okänt (2) 
72. Övrigt/ kommentar: 
(Fritext)  
Statusfynd 
73. Halsvenstas: 
Ja (1) 
Nej (0) 
74. Perifera ödem: 
Ja (1) 
Nej () 
75. Leverförstoring: 
Ja (1) 
Nej (0) 
76. Ascites: 
Ja (1) 
Nej (0) 
77. Perkussionsdämpning: 
Ja (1) 
Nej (0) 
78. Lungrassel/ krepitationer: 
Ja (1) 
Nej (0) 
79. Takypné > 20: 
Ja (1) 
Nej (0) 
80. Cyanos: 
Ja (1) 
Nej (0) 
81. Blåsljud: 
Ja (1) 
Nej (0) 
82. Tarkyardi > 90: 
Ja (1) 
Nej (0) 
83. Tredje ton: 
Ja (1) 
Nej (0) 
 
84. Övriga statusfynd eller  
kommentar:  
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(Fritext) 
 
Genomförda undersökningar och svar 
85.a UCG utfört: 
Ja, transthorakalt (1) 
Ja, transesofagalt (2) 
Nej (0) 
 
85.b Om ja, datum:       
(ÅÅ-MM-DD 
 
 86. Rytm: 
 
 
87. EF: (%) 
 
 
  
88.VK-dialation: 
(med ord) 
Ja (1) 
Nej (0) 
 
89. 
Diameter: 
 
 
 mm 
90. VK-hypertrofi: 
(med ord) 
Ja (1) 
Nej (0) 
 
91. Klaffel: 
 
Ja (1) 
Nej (0) 
92. Lungvensreversering: 
(med ord) 
Ja (1) 
Nej (0) 
93. Decelerationstid < 150 ms: 
 
Ja (1) 
Nej (0) 
 
94. S/D kvot < 1: 
 
Ja (1) 
Nej (0) 
95. E/É: 
 
<8 (1) 
8-15 (2) 
> 15 (3) 
96. Patologisk E/A-kvot: 
(med ord) 
Ja (1) 
Nej (0) 
 
97. Pseudonormaliserad E/A- 
kvot: 
(med ord) 
Ja (1) 
Nej (0) 
98. E/A-kvot: 
 
99. Relaxationsstörning i 
vänster kammare 
(med ord) 
Ja (1) 
Nej (0) 
 
100. Diastolisk dysfunktion: 
(med ord)  
Ja (1) 
Nej (0)  
 
101. Vänster förmak > 40 
ml/m2 
 
Ja (1) 
Nej (0) 
 
102. Måttligt eller kraftigt 
förstorat  
(med ord) 
Ja (1) 
Nej (0) 
103. Vänster förmak yta: 
 
 cm2  
104. Höger förmak dilatation 
 
Ja (1) 
Nej (0) 
 
105. Höger kammar dilatation 
 
Ja (1) 
Nej (0) 
106. Höger förmak yta: 
 
 cm2  
107. BNP/NT-proBNP (ng/l) 
>2000 (1) 
>1800 (2) 
>900 (3) 
108. BNP/NT-proBNP: 
(Högsta värdet som antecknats)  
 
                                            ng/l 
109. Serum kreatinin 
(vid hjärtsvikt) 
 
                                     µmol/L 
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450–900 (4) 
400–450 (5) 
<400 (6) 
Ej taget (7) 
   
 
110. Sviktbild vid lungröntgen/ 
CT thorax 
 
     Ja (1) 
     Nej (0) 
     Ej utfört (2) 
 
111. EKG 
 
Ja (1) 
Nej (0) 
                                
 
112. Rytm  
 
SR (1) 
FF (2)  
PM-ryt (3) 
Övrigt (4) 
113. QRS-bredd: 
 
                     ms 
114. Patologiskt EKG 
 
Ja (1) 
Nej (0) 
115. LBBB: 
 
Ja (1) 
      Nej (0)  
116. RBBB: 
 
Ja (1) 
Nej (0) 
117. Patologisk Q-våg: 
 
Ja (1) 
Nej (0) 
 
118. VK-hypertrofi: 
      
     Ja (1) 
Nej (0) 
119. Pat. R-vågsprogression: 
 
Ja (1) 
Nej (0) 
120. Förlängd QTC-tid: 
 
Ja (1) 
Nej (0) 
 
121. ST-förändringar: 
 
Ja (1) 
Nej (0) 
122. T-förändringar: 
 
Ja (1) 
      Nej (0) 
123. Positivt svar på behandling: 
 
Ja (1) 
Nej (0) 
     Okänt (2) 
124.a Hjärtscintigrafi 
 
Ja (1) 
Nej (0) 
 
 
124.b Om ja:   
(Kommentar)                                                                                 
125.a MR-hjärta: 
 
Ja (1) 
Nej (0) 
 
 
125.b Om ja:   
(Kommentar)                                                                         
126.a Anemi 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
126.b Om ja, HB:   
                                                                                  
g/l 
127. Koronarangiografi 
 
Ja (1)  
      Nej (0) 
 
127.b Om ja:   
(Kommentar)                                                                         
128. Övriga kommentarer: 
(fritext) 
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ÖVRIGA SJUKDOMAR, hjärtsvikt 
 
129. Diabetes 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 130. Hypertoni 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
131. Ischemisk 
hjärtsjukdom 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
 132. Kardimyopatier 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
133. Förmaksflimmer/ 
fladder 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
 134. Obstruktiv 
sömnapné, ev. CPAP-
behandling 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
 
135. KOL eller astma 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
 136. Hyperthyreos 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
 
137. Inflammatorisk 
systemsjukdom 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
 
 
138. Hypothyreos 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
 
 
139. Njurinsufficiens 
(Diagnos i journaltext) 
Ja (1) 
Nej (0) 
 
 140. Serum kreatinin 
(om relevant) 
 
                                                                     µmol/L 
141. Missbruk  
(Ex. alkohol, droger) 
Ja (1) 
Nej (0) 
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142. Annan sjukdom eller kommentar: 
 (Fritext) 
	
	
	
	
